Background: Cardiovascular disease affects 0.2-4% of pregnancies. Coupled with the physiological stress of pregnancy, cardiovascular disease may present significant management challenges including appropriate risk:benefit analysis of medical and surgical management options.
Background
Cardiovascular disease (CVD) affects 0.2-4% of pregnancies and was the leading overall and indirect cause of maternal mortality in the 2014 MMBRACE-UK report. 1,2 CVD coupled with the physiological stressors of pregnancy presents significant management challenges, including availability of appropriate multidisciplinary care, and appropriate balancing of maternal and fetal risks of management options. This case reviews these issues in a patient with CVD secondary to familial hypercholesterolaemia (FH).
Case
A 33-year-old gravida 4 para 1 miscarriage 2 (prior term vaginal birth) presented at 18 weeks' gestation with a history of coronary artery disease (CAD). A coronary CT Angiogram performed four years prior in her country of origin (China) demonstrated 60-70% occlusion of two vessels. This early onset disease was thought to be secondary to known homozygous FH. A pre-pregnancy transthoracic echocardiogram (TTE) demonstrated an 'hour-glass' formation above the aortic root consistent with aortic xanthoma causing mild outflow obstruction, and normal bi-ventricular cardiac function. The patient had been counselled against further pregnancy and was planned for angiography and consideration of cardiac surgery. However, prior to this procedure she became pregnant and declined to proceed with these investigations during pregnancy. She self-ceased statins at the start of pregnancy, and was taking aspirin 100 mg/day and multivitamins only when seen for the first time by our Unit at 18 weeks' gestation. Routine screening bloods were normal, including 75 g glucose tolerance test, and lipid profile is shown in Table 1 . 3 From early pregnancy she complained of shortness of breath and chest pain on exertion, consistent with angina. Metoprolol 25 mg/day was commenced, with good effect. In view of these symptoms, her underlying FH and persistently elevated cholesterol, she recommenced statin therapy (pravastatin 10 mg/day) at 27 weeks' gestation with some reduction in her lipid levels (Table 1 ). Alerts were placed to maternity and critical care services to directly call interventional cardiology if the patient presented with emergent cardiac symptoms.
At 36 weeks' gestation, she experienced further chest discomfort and worsening shortness of breath. Repeat TTE showed no significant changes in cardiac function, and serial troponin and ECG remained normal. After a multidisciplinary meeting, a decision was made to proceed to, induction of labour in the High Dependency Unit at 37 weeks' gestation. She had an elective, assisted, vaginal delivery of a healthy female infant (birthweight 2460 g).
There were no postpartum complications. The patient declined immediate cardiac intervention in order to breastfeed despite counselling regarding the safety of angiography if 24 h of breast milk is discarded post-angiography. As it was likely angiography would be followed shortly afterwards by major cardiac surgery, the patient was concerned she would not be able to establish or continue breastfeeding if she consented to immediate intervention. Therefore, coronary angiogram was finally performed 10 weeks' postpartum and showed 80% occlusion of her left main coronary artery, left anterior descending artery and right coronary artery, and 60% occlusion of her left circumflex artery ( Figure 1 ). The aortic root and ascending aorta demonstrated severe atherosclerosis. She subsequently underwent a triple vessel, off-pump coronary artery bypass, with no aortic manipulation (not attempted given risk of embolisation and stroke) approximately three months after delivery. At review six months' postpartum, she continued to recover well.
Discussion
Generally, women with stable CAD prior to pregnancy will do well, provided they have preserved LV function and are managed with a multidisciplinary team. 4 Fortunately, this patient's outcome was also good; however, the case raises a number of issues including those related to FH and analysis of risks and benefits of potential management approaches, in particular statin use and interventional cardiology.
Effect of FH disease on pregnancy
Heterozygous FH affects 1 in 500 people worldwide. 5 Homozygosity is rare with a prevalence of 1 in 1 million and death usually occurs in the first decade. 5 In our case, the patient was known to be homozygous for an autosomal dominant missense mutation of the LDLR gene, leading to the severe phenotype demonstrated.
Fetal effects of FH are uncertain. Whilst the fetus produces endogenous steroids, up to 20% of its requirements are maternally supplied, with maternal oversupply resulting in increased number and size of fetal pre-atherosclerotic lesions. 3 The association with long-term risk of CVD remains uncertain. 5 Given the need for sterols in fetal development, care should be taken to treat cholesterol levels in the mother to normal pregnancy range and not lower. Hypercholesterolaemia is also a possible cause for recurrent miscarriage and fetal abnormalities. 6 
Effect of pregnancy on FH
Hypercholesterolaemia is a feature of normal pregnancy with an increase of 30-50% in circulating cholesterol levels (Table 1) , which rise from approximately 12 weeks' gestation. Total and LDL cholesterol peak in the mid-second trimester, 3 while HDL-cholesterol and triglycerides rise throughout pregnancy. In conjunction with FH, serum cholesterol can be increased significantly.
This physiological rise appears to have little implication for future CVD, although there is some correlation with hypertension in pregnancy. 7 Moreover, the haemodynamic changes of pregnancy (especially up to 40% increase in cardiac output) 8 put further stress on cardiac function especially in the presence of CAD. This is most important during labour and delivery, where cardiac output further increases and haemodynamic shifts can be sudden and significant. 2 In this case, given the patient's prior vaginal delivery, elective assisted delivery employing regional analgesia and judicious oxytocic use was considered appropriate.
Statin use in pregnancy
In Australia, pravastatin is a category D drug (known or suspected increased incidence of human fetal malformations or irreversible damage), 9, 10 despite no clear evidence of teratogenicity. 8, 9 Statins are therefore routinely discontinued during pregnancy. 4 However, recent studies show no consistent teratogenic pattern in human or animal models given standard regimens, particularly after adjusting for confounders including pre-pregnancy diabetes. 3, 11 Given a lack of proven deleterious effects and the potential for improved pregnancy outcome, statins (particularly pravastatin) are now used on an individualised basis. Trials investigating pravastatin in early-onset pre-eclampsia should provide additional information in the future. 10 This patient was reluctant to take any statin in pregnancy; however, ultimately agreed to take low-dose pravastatin given more pregnancy safety data were available for pravastatin than other agents. As with other HMG-CoA reductase inhibitors, pravastatin reduces hepatic cholesterol synthesis, inducing LDL receptor synthesis and increasing LDL-C cellular uptake. 12 Statins are therefore usually relatively ineffective in FH, requiring high doses. The response seen in this patient (and her survival to reproductive age) may reflect some preservation of enzymatic activity.
Other management issues
Ideally, this patient would have avoided pregnancy until her suspected CAD was reassessed and surgically managed. In reality, she presented to high-risk services at 18 weeks' gestation wishing to avoid fetal risks of maternal disease management. The patient had known CAD and complex aortic root pathologies on previous imaging, but stable symptoms and low estimated risk of acute coronary syndrome. Her complex anomalies suggested the need for hypothermic bypass surgery (rather than angioplasty), with its significant potential for poor fetal outcomes. 13 A strategy of medical therapy with careful monitoring was followed, with a low threshold for angiography if she became unstable. To achieve this required a multidisciplinary team including obstetricians, obstetric physicians, cardiologists, anaesthetists, midwives and intensive care services, and facilities to move to immediate angiographyþ/Àsurgery, if required. Delivery plan was individualised to minimise cardiac stressors and maintain haemodynamic stability, providing the basis for safe term fetal delivery without added maternal complications.
Conclusion
Whilst this case is an example of a rare condition, CVD and its risk factors, including components of the metabolic syndrome such as significant non-familial hyperlipidaemia, are impacting an increasing number of pregnancies. 1 Maternal mortality secondary to ischaemic events is estimated at 5-10%, 1 emphasising the need for a clear management plan from the outset including birth at a unit with appropriate cardiology and critical care facilities and multidisciplinary expertise. Fetal risks of medical and surgical therapies must be balanced against the risk of deterioration of the maternal condition, particularly in cases without proven safe alternatives.
